Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - one of the earliest commercial developers of CAR-T cell therapy technology - in 2013.
presented by
The Top Surgical Instruments Needed for Extractions
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Venture capital firm Omega Funds closes $438M Fund VI
In a phone interview, Managing Director Otello Stampacchia noted that the firm has already invested some money from Fund VI in biopharma startups.
Kronos Bio bags $105M in Series A round for platform technology
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Single-letter gene editing startup Beam Therapeutics raises $135M Series B round
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Morphic raises $80M in Series B round to fund oral integrin inhibitor development
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
Q&A with founder of Omega Funds, the reclusive VC firm behind Juno, Gossamer Bio, and Editas
Having co-led the $100 million Series A transaction in Gossamer Bio, the founder of Omega Funds believes its time for the fund to come out of its protective shell.
Is too much money being invested in oncology?
Oncology startups are raking in lion's share of early-stage capital and recent M&A's have also been heavily weighted toward oncology. Is too much capital going to overcome cancer?
Navigating The Right Steps For Your Healthcare Startup
This webinar will explore how a banking platform approach could be the resource for your company.